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Abstract
BACKGROUND—Hydroxyurea is an effective treatment for sickle cell anemia, but few studies 
have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting conditions 
such as malnutrition and malaria may affect the feasibility, safety, and benefits of hydroxyurea in 
low-resource settings.
METHODS—We enrolled children 1 to 10 years of age with sickle cell anemia in four sub-
Saharan countries. Children received hydroxyurea at a dose of 15 to 20 mg per kilogram of body 
weight per day for 6 months, followed by dose escalation. The end points assessed feasibility 
(enrollment, retention, and adherence), safety (dose levels, toxic effects, and malaria), and benefits 
(laboratory variables, sickle cell–related events, transfusions, and survival).
RESULTS—A total of 635 children were fully enrolled; 606 children completed screening and 
began receiving hydroxyurea at a mean (±SD) dose of 17.5±1.8 mg per kilogram per day. The 
retention rate was 94.2% at 3 years of treatment. Hydroxyurea therapy led to significant increases 
in both the hemoglobin and fetal hemoglobin levels. Dose-limiting toxic events regarding 
laboratory variables occurred in 5.1% of the participants, which was below the protocol-specified 
threshold for safety. During the treatment phase, 20.6 dose-limiting toxic effects per 100 patient-
years occurred, as compared with 20.7 events per 100 patient-years before treatment. As compared 
with the pretreatment period, the rates of clinical adverse events decreased with hydroxyurea use, 
including rates of vaso-occlusive pain (98.3 vs. 44.6 events per 100 patient-years; incidence rate 
ratio, 0.45; 95% confidence interval [CI], 0.37 to 0.56), nonmalaria infection (142.5 vs. 90.0 
events per 100 patient-years; incidence rate ratio, 0.62; 95% CI, 0.53 to 0.72), malaria (46.9 vs. 
22.9 events per 100 patient-years; incidence rate ratio, 0.49; 95% CI, 0.37 to 0.66), transfusion 
(43.3 vs. 14.2 events per 100 patient-years; incidence rate ratio, 0.33; 95% CI, 0.23 to 0.47), and 
death (3.6 vs. 1.1 deaths per 100 patient-years; incidence rate ratio, 0.30; 95% CI, 0.10 to 0.88).
CONCLUSIONS—Hydroxyurea treatment was feasible and safe in children with sickle cell 
anemia living in sub-Saharan Africa. Hydroxyurea use reduced the incidence of vaso-occlusive 
events, infections, malaria, transfusions, and death, which supports the need for wider access to 
treatment. (Funded by the National Heart, Lung, and Blood Institute and others; REACH 
ClinicalTrials.gov number, NCT01966731.)
SICKLE HEMOGLOBINOPATHIES ARE COMmon and life-threatening genetic disorders. 
Homozygous hemoglobin S (HbSS) is the most severe genotype, and together with 
hemoglobin Sβ0 thalassemia, is called sickle cell anemia.1 On deoxygenation, erythrocytes 
become sickle-shaped, rigid, adhesive, and prone to lysis; blood flow is blocked within small 
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vessels, leading to ischemic tissue injury.1 In the United States, approximately 100,000 
persons are affected,2 most of whom have numerous acute and chronic medical 
complications that lead to poor quality of life and early death.1,3 On a global scale, the 
incidence of sickle hemoglobinopathies is greatest in sub-Saharan Africa, with more than 
300,000 babies with sickle cell disease born annually, representing approximately 1% of 
births in the region.4
In high-resource settings such as the United States and Europe, as well as Jamaica and other 
Caribbean settings, the early identification of children with sickle cell anemia by means of 
neonatal screening allows for comprehensive care that includes simple, effective, and 
lifesaving interventions with penicillin prophylaxis, pneumococcal immunizations, and 
caregiver education.5-7 The advent of routine transcranial Doppler screening to identify 
children at risk for stroke, along with access to safe erythrocyte transfusions, has further 
contributed to marked decreases in morbidity.8 To date, however, very few settings in sub-
Saharan Africa have established screening programs for sickle cell anemia, and specialized 
treatment is available at only a few large, urban centers.
Hydroxyurea was first shown to induce fetal hemoglobin production more than 30 years 
ago9 and is now a Food and Drug Administration–approved treatment for sickle cell anemia 
in both children (Siklos, Addmedica) and adults (Hydrea and Droxia, Bristol-Myers 
Squibb). By means of the induction of fetal hemoglobin and other beneficial changes, 
including mild myelosuppression, hydroxyurea therapy has been shown to have clinical 
efficacy in reducing the incidence of acute vaso-occlusive events,10,11 ameliorating chronic 
organ damage,12 and prolonging survival.13,14 Evidence-based guidelines from the National 
Heart, Lung, and Blood Institute recommend offering hydroxyurea treatment to persons with 
sickle cell anemia as early as 9 months of age.15
Whether hydroxyurea will be safe and effective in Africa is unclear. Coexisting conditions 
such as malaria, other infectious diseases that are endemic to the area, and malnutrition may 
increase the incidence of toxic effects and limit treatment responses. We conducted an 
international trial, Realizing Effectiveness across Continents with Hydroxyurea (REACH), 
to investigate the feasibility, safety, and benefits of hydroxyurea treatment for children with 
sickle cell anemia living in sub-Saharan Africa.
METHODS
TRIAL DESIGN
We designed this phase 1–2, open-label, international trial to assess the feasibility, safety, 
and benefits of hydroxyurea treatment in young children with sickle cell anemia living in 
sub-Saharan Africa. The two-stage trial design has been described previously16 and included 
a built-in pause in enrollment to ensure the safety of the initial dose level (Fig. S1 in the 
Supplementary Appendix, available with the full text of this article at NEJM.org). Children 1 
to 10 years of age were recruited at four clinical trial sites in sub-Saharan Africa (Hospital 
Pediátrico David Bernardino in Luanda, Angola; Centre Hospitalier Monkole in Kinshasa, 
Democratic Republic of Congo; Kilifi District Hospital in Kilifi, Kenya; and Mbale 
Regional Referral Hospital in Mbale, Uganda), with a goal of treating 150 participants per 
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site with once-daily oral hydroxyurea. At each site, enrollment was paused to allow for the 
evaluation of the 3-month incidence of hematologic toxic effects among the first 53 
participants enrolled.16
The protocol (available at NEJM.org) was designed by the authors and approved by all 
appropriate institutional review boards or ethics committees, as well as by national 
regulatory groups. A parent or legal guardian provided written informed consent for each 
participant to enroll and begin the screening process. A full list of the investigative teams, 
including the physicians, nurses, pharmacists, and laboratory and data personnel who 
received specific protocol training, is provided in the Supplementary Appendix. Local trial 
teams collected the data, which were monitored and analyzed by the data management 
center. The first draft of the manuscript was written by the first and last authors, with 
contributions by all the authors. All the authors made the decision to submit the manuscript 
for publication. The sponsors had no oversight or involvement in data collection and analysis 
or in the writing and submission of the manuscript. The last author vouches for the accuracy 
and completeness of the data and for the fidelity of the trial to the protocol.
DRUG TREATMENT AND DOSE ESCALATION
Hydroxyurea capsules were donated by Bristol-Myers Squibb, which had no role in the trial 
design or conduct, the data collection or analysis, or the manuscript preparation or review. 
After a 2-month screening period that was used to collect pretreatment clinical and 
laboratory data, the starting dose of hydroxyurea was 15 to 20 mg per kilogram of body 
weight per day. After 6 months of treatment, the hydroxyurea dose was escalated by 2.5 to 
5.0 mg per kilogram per day every 2 months on the basis of peripheral-blood counts to 
determine a maximum tolerated dose, which was defined as a stable daily dose that caused 
mild bone marrow suppression without toxic effects — typically, an absolute neutrophil 
count of less than 4000 per cubic millimeter. To ensure the safety of the participants, the 
dose level was monitored at each visit by trial staff, who entered the results of the complete 
blood count and reticulocyte count into an interactive online calculator tool before the drug 
was dispensed.
END POINTS
The primary safety end point was hematologic dose-limiting toxic effects in the first 3 
months of hydroxyurea treatment in the first 133 children enrolled at each clinical trial site; 
the expected and allowable rates of this end point were 20% and 30%, respectively, on the 
basis of published toxicity data, with type I and II error rates of 10%.16 Protocol-specified 
thresholds for toxic effects involving laboratory variables included a hemoglobin level of 
less than 4.0 g per deciliter, an absolute neutrophil count of less than 1000 per cubic 
millimeter, an absolute reticulocyte count of less than 80,000 per cubic millimeter unless the 
hemoglobin level was more than 7.0 g per deciliter, and a platelet count of less than 80,000 
per cubic millimeter. Additional trial end points included assessments of feasibility 
(enrollment, retention, and adherence), safety (dose levels, toxic effects, and malaria), and 
benefits (laboratory variables, sickle cell–related events, transfusions, and survival).
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DATA COLLECTION AND STORAGE
All the trial data were collected and entered into a REDCap Internet-based data-capture 
system. Separate REDCap environments were developed in English, Portuguese, and 
French, which were the official languages at each clinical site.16 Data on clinical adverse 
events of grade 2 or higher were collected during both the screening (pretreatment) phase 
and the treatment phase. Trial monitoring used a remote system and on-site evaluations. 
Data on adverse events were collected and curated, with review of source documentation 
whenever available. Deaths were further evaluated with the use of the World Health 
Organization (WHO) verbal autopsy form that has previously been validated for children 
with sickle cell anemia.17
STATISTICAL ANALYSIS
The Simon two-stage design for the primary safety end point (hematologic dose-limiting 
toxic effects in the first 3 months of hydroxyurea treatment) has been described previously.16 
Secondary end points regarding feasibility, safety, and benefits were summarized with means 
and standard deviations or percentages, as appropriate. We used a competing-risk approach 
to estimate the cumulative incidence of death or withdrawal. Laboratory values at baseline 
and at 12 months were compared by Student’s t-test. Rates of clinical adverse events during 
the pretreatment phase and during the treatment phase were presented as the number of 
events per 100 patient-years and compared by the incidence rate ratio with 95% confidence 
intervals, all of which were calculated from Poisson regression with the use of generalized 
estimating equations to account for clustering and overdispersion. A similar approach was 
used to show the effect of increasing treatment duration, with events and time at risk during 
treatment divided into consecutive 6-month intervals. There were no adjustments for 
multiple comparisons. All the statistical analyses were performed with the use of R software, 
version 3.4.4.
RESULTS
ENROLLMENT AND RETENTION
All four trial sites proceeded to the second stage of the trial and met their enrollment goals. 
A total of 635 children had consent provided by a parent or guardian and entered screening, 
606 children completed screening and began receiving hydroxyurea treatment, and 600 
children (99.0%) completed 3 months of the trial treatment (Fig. 1). The overall retention 
rate in the trial was 94.2% at 3 years of treatment (Fig. 2). A total of 33 children (5.4%) 
withdrew from the trial after treatment initiation. More than 98% of the trial visits were 
completed, including 91% within the scheduled visit window.
HYDROXYUREA DOSE
The initial mean (±SD) dose of hydroxyurea that was administered was 17.5±1.8 mg per 
kilogram per day, which was within the protocol-directed starting dose range of 15 to 20 mg 
per kilogram per day. The initial dose was fixed for 6 months in all the participants to allow 
for the assessment of laboratory and clinical adverse events. Dose escalation began at month 
6, and to date, 515 children (85.0%) have reached a mean maximum tolerated dose of 
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22.5±4.9 mg per kilogram per day, with the dose ranging from 18.9±4.2 mg per kilogram 
per day in Angola to 25.3±4.8 mg per kilogram per day in Uganda. The mean time to 
reaching the maximum tolerated dose was 11±4 months, and the mean overall treatment 
duration was 29±9 months. The rate of adherence to medication was assessed at each 
scheduled visit, and more than 90% of assessments documented no missed doses. A brief 
drug shortage between February and April 2016 affected the administration of the 
medication at three sites but had no influence on the primary end point (Table S1 in the 
Supplementary Appendix).
ADVERSE EVENTS
Laboratory monitoring at scheduled visits and at unscheduled visits for illness identified 
dose-limiting toxic effects during the screening phase (a total of 2012 complete blood counts 
were performed over a period of 111 patient-years) and during the treatment phase (a total of 
13,589 complete blood counts were performed over a period of 1469 patient-years). 
Hematologic dose-limiting toxic effects during the first 3 months (the primary safety end 
point) occurred in 5.1% of the participants overall, with the rate at each site being well 
below the protocol-specified thresholds for toxic events regarding laboratory variables. The 
rates of these safety events differed across sites, ranging from 0.8% to 8.3% (P = 0.01 by 
Fisher’s exact test) (Table S2 in the Supplementary Appendix), and the random-effects 
pooled estimate was 4.5% (95% confidence interval [CI], 2.3 to 8.8). No significant 
differences between the screening and treatment phases were found with regard to the 
individual laboratory toxic-effect variables (Table 1), but slight differences were noted 
between sites (data not shown).
LABORATORY BENEFITS
Laboratory variables at baseline revealed anemia with expected leukocytosis and 
reticulocytosis (Table 2). After 1 year of hydroxyurea treatment, the participants had 
significant increases in the hemoglobin level (increase of 1.0 g per deciliter; 95% CI, 0.8 to 
1.0), the mean corpuscular volume (increase of 13 fl; 95% CI, 12 to 13), and the fetal 
hemoglobin level (increase of 12.5%; 95% CI, 11.8 to 13.1). During hydroxyurea treatment, 
the white-cell count, absolute neutrophil count, and absolute reticulocyte count significantly 
decreased, reflecting the intended mild bone marrow suppression, and these effects were 
sustained over time (Table 2). Similar results were recorded at each individual clinical trial 
site (data not shown).
CLINICAL BENEFITS
Comparison of event rates between the screening and treatment phases revealed significant 
reductions in the incidence of all clinical adverse events (308.4 vs. 170.7 events per 100 
patient-years; incidence rate ratio, 0.54; 95% CI, 0.48 to 0.62) and serious adverse events 
(10.8 vs. 4.4 events per 100 patient-years; incidence rate ratio, 0.47; 95% CI, 0.25 to 0.90) 
during hydroxyurea treatment. The investigators did not consider any of the adverse events 
or serious adverse events to be related to hydroxyurea treatment.
The overall rate of sickle cell–related events was significantly reduced (114.5 vs. 53.0 events 
per 100 patient-years; incidence rate ratio, 0.47; 95% CI, 0.38 to 0.57), and the rates of vaso-
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occlusive pain and the acute chest syndrome were both reduced (Table 1). The rates of 
infection also declined, including rates of nonmalaria infection (142.5 vs. 90.0 events per 
100 patient-years; incidence rate ratio, 0.62; 95% CI, 0.53 to 0.72) and severe infection of 
grade 3 or higher (28.9 vs. 8.0 events per 100 patient-years; incidence rate ratio, 0.28; 95% 
CI, 0.19 to 0.42).
EFFECTS ON SURVIVAL
Analyses of additional key clinical events revealed significant reductions during 
hydroxyurea treatment in the rate of malaria infections (46.9 vs. 22.9 events per 100 patient-
years; incidence rate ratio, 0.49; 95% CI, 0.37 to 0.66), blood transfusion (43.3 vs. 14.2 
events per 100 patient-years; incidence rate ratio, 0.33; 95% CI, 0.23 to 0.47), and death (3.6 
vs. 1.1 events per 100 patient-years; incidence rate ratio, 0.30; 95% CI, 0.10 to 0.88). When 
grouped into 6-month time intervals, the rates of multiple life-threatening clinical events 
declined rapidly after the initiation of hydroxyurea therapy and dose escalation, with a 
sustained or improved benefit. Reductions in event rates over time were noted for all sickle 
cell–related clinical events, malaria, vaso-occlusive pain, transfusion, the acute chest 
syndrome, and death from any cause (Fig. 3).
DISCUSSION
In this trial involving children with sickle cell anemia living in sub-Saharan Africa, we 
found that hydroxyurea treatment was feasible, reasonably safe, and had both laboratory and 
clinical benefits. Specifically, as compared with pretreatment rates, the rates of clinical 
events, including vaso-occlusive pain, infection, malaria, transfusion, and death, declined 
after 1 year of hydroxyurea treatment.
Enrollment was robust at all the clinical trial sites, with enthusiasm and support from local 
clinical research teams and populations of patients, which showed the feasibility of 
conducting a large-scale clinical trial in sub-Saharan Africa. Hematologic dose-limiting 
toxic effects during the first 3 months of treatment (the primary safety end point) occurred in 
only a small number of participants, and the hydroxyurea dose was then safely escalated 
toward a maximum tolerated dose, similar to treatment protocols in the United States.15 
Expected hematologic benefits occurred, with significant increases in the hemoglobin and 
fetal hemoglobin levels. Significant reductions were observed in the incidence rates of sickle 
cell–related clinical events, including vaso-occlusive pain, and major clinical events 
including infection, malaria, transfusion, and death. No serious adverse events or deaths 
were considered by the investigators to be related to hydroxyurea treatment (Tables S3 and 
S4 in the Supplementary Appendix).
In the United States and Europe, hydroxyurea has emerged as a potent, disease-modifying 
therapy with regulatory approvals for use in both children and adults. Although the primary 
mode of action of hydroxyurea is through the induction of fetal hemoglobin, this drug has 
multiple salutary effects on erythrocytes, leukocytes, and even endothelium that make it a 
beneficial oral treatment for this life-threatening disease, especially at the maximum 
tolerated dose.18 The WHO includes hydroxyurea on its Model Lists of Essential Medicines 
for children and adults for the treatment of sickle hemoglobinopathies,19,20 which provides 
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an impetus for widespread use on a global scale. To date, however, few studies have been 
completed in sub-Saharan Africa or other low-income settings where the burden of sickle 
cell disease is greatest.21 In addition to several small studies of hydroxyurea conducted in 
Nigeria,22-24 the Novel Use of Hydroxyurea in an African Region with Malaria (NOHARM) 
trial was a randomized, double-blinded, placebo-controlled trial that was conducted at a 
single, large, urban site in Uganda, which showed that the rates of malaria were not higher 
with hydroxyurea than with placebo.25 However, the overall incidence of malaria in the 
NOHARM trial was very low, whereas the participants in the REACH trial lived in urban 
and rural areas of Africa that have a much higher incidence of malaria than Kampala, 
Uganda, where the NOHARM trial was conducted.
With full enrollment, high rates of adherence to trial visits and medication use, and a 
retention rate of nearly 95% in the trial over a period of 3 years, our trial showed that 
hydroxyurea treatment was both feasible and safe in sub-Saharan Africa. Despite frequent 
laboratory monitoring, dose-limiting toxic effects were uncommon in the first 3 months of 
treatment, and then the incidence did not increase further (Table 1). After 6 months of fixed-
dose hydroxyurea therapy, dose escalation was not associated with unacceptable side effects 
or with toxic effects regarding laboratory variables and reached daily doses that were similar 
to those reported in the United States.26,27 Our results indicate that a daily dose of 
approximately 20 mg per kilogram per day was reasonably effective and not associated with 
dose-limiting toxic effects. The trial was not designed to determine the appropriate amount 
or frequency of laboratory monitoring.
The laboratory benefits of hydroxyurea treatment were evident, despite relative malnutrition 
in the REACH cohort, as compared with WHO childgrowth standards and with populations 
of patients with sickle cell disease in the United States and Europe. Expected significant 
increases were observed in both the hemoglobin and fetal hemoglobin levels, along with 
significant decreases in the absolute neutrophil and reticulocyte counts, and these changes 
were sustained over time (Table 2). The mean increase in the hemoglobin level of 1 g per 
deciliter, despite suboptimal nutrition and ongoing risks of malaria and other infections, is 
important because the hemoglobin level is a well-established predictor of adverse outcomes 
in children with sickle cell anemia.28 Within 6 months after the start of treatment, expected 
clinical benefits were also observed with regard to sickle cell–related events such as pain and 
the acute chest syndrome, as well as all severe (grade ≥3) adverse events.
The benefits of hydroxyurea therapy with regard to malaria infections were significant — 
with a rate reduction of more than 50% — and were not predicted before the trial (Table 1), 
despite the lack of malaria chemoprophylaxis programs at all the clinical sites. This benefit 
was especially notable after 12 months of treatment, so it may reflect known inhibitory 
effects of fetal hemoglobin,29 more than direct effects by hydroxyurea,30 on parasite growth. 
The importance of this effect should be evident for sub-Saharan Africa, where Plasmodium 
falciparum malaria is a major killer of children and is especially lethal in those with sickle 
cell anemia.31 In a finding that perhaps reflects the decrease in the incidence of malaria, 
there was a significant reduction in the incidence of transfusions (Table 1), which is 
important because of the general lack of safe blood supply across Africa.32
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This trial showed a significant reduction in all-cause mortality in this young cohort (Table 
1). This effect reflects the combined effect of fewer severe sickle cell–related clinical 
complications, infections, malaria, and possibly transfusions. However, because the REACH 
trial did not include a placebo control, the survival benefit could be due to hydroxyurea use 
but also to better overall care, since the participants had frequent visits while they were 
receiving treatment. However, these findings are similar to those of previous reports that 
have shown an effect of hydroxyurea therapy on survival.13,14,33,34
A limitation of this trial was the open-label treatment design without randomization or a 
placebo control, which was a decision that was based on strong opinions from the local 
ethics boards. However, the design fully addressed the key end points of feasibility and 
safety, showing that hydroxyurea could be administered in low-resource settings. All the 
participants received good care with close monitoring, which probably contributed to better 
outcomes that were unrelated to hydroxyurea treatment; additional studies will be needed to 
confirm sustained benefits with less monitoring. Strengths of this trial included the 
following: the international design; the dosing algorithm of a fixed dose followed by 
escalation to the maximum tolerated dose; the use of an electronic-capture system for data 
entry; and the availability of an online dose calculator to help ensure the safety of the 
participants. Long-term follow-up of this African cohort is ongoing for the investigation of 
growth and development and possible effects on organ function and fertility.
In conclusion, our results show that daily hydroxyurea treatment was feasible and safe for 
children with sickle cell anemia in sub-Saharan Africa. Moreover, hydroxyurea treatment 
reduced the rates of painful events, infection, malaria, transfusion, and death. Despite the 
recognition that 50 to 90% of affected children in Africa die before the age of 5 years,35 
sickle cell anemia remains a neglected disease for which safe and effective treatment options 
are needed.36 As countries in sub-Saharan Africa begin newborn screening programs to 
identify children with sickle cell anemia,37-39 wider access to hydroxyurea may provide a 
simple and inexpensive oral medication that can alter the disease course and prolong 
survival.
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Figure 1. Screening, Enrollment, and Follow-up of the Participants.
The numbers of patients who withdrew from the trial or died are from the group of patients 
who completed treatment up to the respective time point.
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Figure 2. Retention of Participants in the Trial.
The shaded area represents the 95% confidence interval for death or withdrawal from the 
trial. The inset shows the same data on an enlarged y axis.
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Figure 3. Adverse Events before and during Hydroxyurea Treatment.
Error bars indicate 68% confidence intervals, which correspond to approximately 1 standard 
error.
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